<DOC>
	<DOCNO>NCT01768338</DOCNO>
	<brief_summary>The purpose study test safety rhIL-18 combined ofatumumab see effect ( good bad ) subject non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Recombinant Human IL-18 Ofatumumab After PBSCT Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients undergo highdose therapy autologous PBSCT treatment CD20+ lymphoma . Patients must 26 month posttransplantation time study registration . Patients must least stable disease ( overt progressive disease ) time study registration . Laboratory value must within protocol specify range . Females childbearing potential must negative pregnancy test . Females childbearing potential male must use effective method contraception time consent least 365 day follow discontinuation protocol therapy . Patient must obvious clinical progression lymphoma PBSCT determine treat physician . Can positive hepatitis B surface antigen , hepatitis B core antibody HIV antibody . No major uncontrolled comorbid condition determine treat physician : history ventricular arrhythmia require drug device therapy ; uncontrolled angina symptomatic congestive heart failure ; â€¢ severe uncontrolled infection require systemic antibiotic antifungal therapy active hepatitis C infection ; severe uncontrolled psychiatric illness . No known leptomeningeal involvement lymphoma current metastatic brain disease . No Corrected QTc interval &gt; 480 msec . No know suspect hypersensitivity ofatumumab SB485232 opinion investigator contraindication participation study . No systemic ( oral parenteral ) corticosteroid within 14 day study entry . Not receive concurrent chemotherapy , biologic therapy , radiotherapy , investigational therapy . No previous treatment SB485232 ofatumumab . No history malignancy except adequately treat noninvasive cancer skin ( basal squamous cell ) carcinoma situ uterine cervix . No diabetes mellitus poor glycemic control ( document hemoglobin A1c &gt; 7 % within 4 week prior study entry ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>